证券代码：600566 证券简称：济川药业 公告编号： 2025-060 特此公告。 湖北济川药业股份有限公司董事会 湖北济川药业股份有限公司(以下简称"公司")于 2025年6月16日披露了《要约收购报告书》等相关文 件。曹飞先生向除曹龙祥先生、江苏济川控股集团有限公司(以下简称"济川控股")及西藏济川企业管理 有限公司(以下简称"西藏济川")以外的其他股东发出收购其所持有的上市公司全部无限售条件流通股的 全面要约。本次要约收购股份数量为350,841,357股，占公司总股本的 38.06%,要约收购价格为24.85元/ 股(基于 2024年度利润分配方案实施完成，本次要约收购价格由26.93元/股调整为24.85 元/股)。要约收 购期限为 2025年6月18 日至2025年7月17日。 截至2025年7月17日，本次要约收购期限届满。根据中国证券登记结算有限责任公司上海分公司（以下 简称"中登上海分公司"）提供的数据统计，在本次要约收购期限内，预受要约的股东账户总数为34户， 预受要约股份总数共计 16,300 股，占公司总股本的 0.0018%。 曹飞先生已按照上海证券交易所和中登上海分公司的有关规定 ...

Core Points - As of July 31, 2025, Jichuan Pharmaceutical's stock price closed at 26.85 yuan, down 0.70 yuan or 2.54% from the previous trading day [1] - The company reported a trading volume of 101,562 hands and a transaction amount of 275 million yuan on the same day [1] Company Overview - Jichuan Pharmaceutical is primarily engaged in the research, development, production, and sales of pharmaceuticals, covering both traditional Chinese medicine and chemical drugs [1] - The company's business segments include traditional Chinese medicine, Hubei region, and influenza [1] Shareholding Changes - On July 31, Jichuan Pharmaceutical announced that the share acquisition by Cao Fei has been completed [1] - Following the completion of the acquisition, Cao Fei directly and indirectly controls a total of 517 million shares, accounting for 56.07% of the company's total share capital [1] - Cao Fei and his concerted party, Cao Longxiang, jointly control 564 million shares, representing 61.15% of the total share capital [1] Market Activity - On the same day, the net outflow of main funds was 10.0462 million yuan, accounting for 0.04% of the circulating market value [1]

Core Points - The announcement details the completion of the share acquisition by Mr. Cao Fei, who made a comprehensive offer to acquire all unrestricted circulating shares from shareholders other than certain specified parties [1][2] - The total number of shares offered for acquisition was 350,841,357, representing 38.06% of the company's total share capital, with an adjusted offer price of 24.85 yuan per share [1] - The acquisition period was set from June 18, 2025, to July 17, 2025 [1] Summary of Acquisition Results - By the end of the acquisition period on July 17, 2025, a total of 34 shareholder accounts accepted the offer, amounting to 16,300 shares, which is only 0.0018% of the total share capital [2] - Following the completion of the acquisition, Mr. Cao Fei directly holds 16,300 shares and indirectly controls 416,757,360 shares through his controlled entity, Jichuan Holdings, and 100,000,000 shares through another entity, Tibet Jichuan [2] - In total, Mr. Cao Fei directly and indirectly controls 516,773,660 shares, which is 56.07% of the company's total share capital, while he and his concerted actor, Mr. Cao Longxiang, collectively control 563,612,118 shares, accounting for 61.15% of the total share capital [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北济川药业股份有限公司(以下简称"公司")于 2025 年 6 月 16 日披露 了《要约收购报告书》等相关文件。曹飞先生向除曹龙祥先生、江苏济川控股集 团有限公司(以下简称"济川控股")及西藏济川企业管理有限公司(以下简称"西 藏济川")以外的其他股东发出收购其所持有的上市公司全部无限售条件流通股 的全面要约。本次要约收购股份数量为 350,841,357 股，占公司总股本的 38.06%, 要约收购价格为 24.85 元/股(基于 2024 年度利润分配方案实施完成，本次要约 收购价格由 26.93 元/股调整为 24.85 元/股)。要约收购期限为 2025 年 6 月 18 日至 2025 年 7 月 17 日。 截至 2025 年 7 月 17 日，本次要约收购期限届满。根据中国证券登记结算有 限责任公司上海分公司（以下简称"中登上海分公司"）提供的数据统计，在本 次要约收购期限内，预受要约的股东账户总数为 34 户，预受要约股份总数共计 曹飞先生已按照上海证券交易所 ...

金融界消息 截至2025年7月31日收盘，济川药业（600566）报收于26.85元，下跌2.54%，换手率 1.11%，成交量10.16万手，成交金额2.75亿元。 资金流向方面，今日主力资金净流出1004.62万元，占比成交额3.66%。其中，超大单净流出1047.13万 元、占成交额3.81%，大单净流入42.51万元、占成交额0.15%，中单净流出流入129.69万元、占成交额 0.47%，小单净流入874.93万元、占成交额3.19%。 济川药业最新一期业绩显示，截至2025一季报，公司营业总收入15.25亿元、同比减少36.51%，归属净 利润4.40亿元，同比减少47.91%，扣非净利润3.92亿元，同比减少46.01%，流动比率4.934、速动比率 4.780、资产负债率17.27%。 天眼查商业履历信息显示，湖北济川药业股份有限公司，成立于1997年，位于荆州市，是一家以从事医 药制造业为主的企业。企业注册资本92241.816万人民币，实缴资本56359.5818万人民币。公司法定代表 人为曹龙祥。 通过天眼查大数据分析，湖北济川药业股份有限公司共对外投资了3家企业，参与招投标项目36次， ...

证券代码：600566 证券简称：济川药业 公告编号： 2025-060 湖北济川药业股份有限公司 关于曹飞先生要约收购公司股份交割完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北济川药业股份有限公司(以下简称"公司")于 2025 年 6 月 16 日披露 了《要约收购报告书》等相关文件。曹飞先生向除曹龙祥先生、江苏济川控股集 团有限公司(以下简称"济川控股")及西藏济川企业管理有限公司(以下简称"西 藏济川")以外的其他股东发出收购其所持有的上市公司全部无限售条件流通股 的全面要约。本次要约收购股份数量为 350,841,357 股，占公司总股本的 38.06%, 要约收购价格为 24.85 元/股(基于 2024 年度利润分配方案实施完成，本次要约 收购价格由 26.93 元/股调整为 24.85 元/股)。要约收购期限为 2025 年 6 月 18 日至 2025 年 7 月 17 日。 截至 2025 年 7 月 17 日，本次要约收购期限届满。根据中国证券登记结算有 限责任公司上海分公司（以下简称" ...

济川药业公告，曹飞先生向除曹龙祥先生、江苏济川控股集团有限公司及西藏济川企业管理有限公司以 外的其他股东发出收购其所持有的上市公司全部无限售条件流通股的全面要约。本次要约收购股份数量 为3.51亿股，占公司总股本的38.06%，要约收购价格为24.85元/股。要约收购期限为2025年6月18日至 2025年7月17日。截至2025年7月17日，预受要约的股东账户总数为34户，预受要约股份总数共计16300 股，占公司总股本的0.0018%。曹飞先生已按照规定履行了相关义务，本次要约收购清算过户手续已经 办理完毕，曹飞先生直接持有公司16300股股份，通过其控制的济川控股间接控制上市公司4.17亿股股 份、通过其控制的西藏济川间接控制上市公司1亿股股份。曹飞先生直接及间接控制公司5.17亿股股 份，占公司总股本的56.07%。曹飞先生及其一致行动人曹龙祥先生共同控制公司5.64亿股股份，占公司 总股本的61.15%。 ...

天眼查商业履历信息显示，湖北济川药业股份有限公司，成立于1997年，位于荆州市，是一家以从事医 药制造业为主的企业。企业注册资本92241.816万人民币，实缴资本56359.5818万人民币。公司法定代表 人为曹龙祥。 通过天眼查大数据分析，湖北济川药业股份有限公司共对外投资了3家企业，参与招投标项目36次，专 利信息43条，此外企业还拥有行政许可1个。 来源：金融界 金融界消息 截至2025年7月30日收盘，济川药业（600566）报收于27.55元，上涨0.92%，换手率1.4%， 成交量12.80万手，成交金额3.55亿元。 资金流向方面，今日主力资金净流出1535.11万元，占比成交额4.33%。其中，超大单净流出223.94万 元、占成交额0.63%，大单净流出1311.18万元、占成交额3.7%，中单净流出流入1280.99万元、占成交 额3.61%，小单净流入254.12万元、占成交额0.72%。 济川药业最新一期业绩显示，截至2025一季报，公司营业总收入15.25亿元、同比减少36.51%，归属净 利润4.40亿元，同比减少47.91%，扣非净利润3.92亿元，同比减少46.01%，流动比 ...

Core Viewpoint - The company has recently launched two new drugs, Maraslosavir Tablets and Pediatric Constipation Granules, which are categorized as innovative drugs and are expected to impact the company's performance positively [2]. Group 1: Drug Development and Approval - Maraslosavir Tablets is a Class 1 new chemical drug developed in collaboration with Nanjing Zhengxiang Pharmaceutical Co., Ltd., and has been approved for market launch [2]. - Pediatric Constipation Granules is a Class 1 innovative traditional Chinese medicine that has had its market approval application accepted, and the company is actively working on subsequent processes [2]. Group 2: Market Impact and Risks - The sales of these products may be influenced by changes in domestic pharmaceutical industry policies, tender procurement, and market environment, indicating potential uncertainties in their market performance [2].

Core Viewpoint - The transition of control at Jichuan Pharmaceutical has led to a dramatic response from shareholders, with only 34 out of 19 billion yuan in margin deposits being accepted, highlighting the company's significant challenges in product performance and financial stability [1] Financial Performance - In 2024, Jichuan Pharmaceutical reported revenue of 8.017 billion yuan, a year-on-year decline of 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [1] - For Q1 2025, the company experienced further declines, with revenue of 1.525 billion yuan, a 36.51% decrease year-on-year, and a net profit of 440 million yuan, down 47.91% [1] Product Challenges - The company's key products, which previously supported a compound annual growth rate of 21.49% in net profit, are now facing significant declines, particularly the flagship product, Pudilan Oral Liquid, which saw a 24% drop in sales in 2019 after regulatory changes [2] - The product has been removed from the medical insurance directories of 13 provinces, leading to a more than 20% decline in revenue from heat-clearing and detoxifying products in 2024 [2] - The digestive product, Rabeprazole Sodium Enteric-Coated Capsules, has lost market share due to price reductions from national procurement, with inventory levels rising by 23.85% in 2024 [3] Operational Efficiency - Jichuan Pharmaceutical's inventory turnover days and accounts receivable turnover days reached new highs of 114.61 days and 110.01 days, respectively, indicating a decline in operational efficiency [3] - The net cash flow from operating activities as a percentage of total revenue fell sharply from 35.88% in 2023 to 27.15% in 2024, marking a three-year low [3] Marketing vs. R&D Investment - The company has prioritized marketing over research and development, spending 2.954 billion yuan on sales expenses in 2024, which accounted for 36.85% of revenue, while R&D investment was only 445 million yuan, representing 5.55% of revenue [4] - The disparity is evident as the company distributed 5 billion yuan in dividends over five years, with the controlling family benefiting significantly, raising concerns about the sustainability of this cash distribution model [5] Future Prospects - Jichuan Pharmaceutical's pipeline includes the pediatric constipation drug, which faces multiple commercialization challenges, and other innovative drugs that are still in the application stage [6] - The company must address a significant revenue gap due to the underperformance of its key products, as new drugs may not provide immediate relief from the current downturn [6]